Obstáculos en la comunicación entre el cerebro y el intestino: Predictores biopsicosociales de la calidad de vida en el síndrome del intestino irritable by Pletikosić Tončić, Sanda et al.
Psychological Topics, 27 (2018), 1, 91-114 
Original Scientific Paper – UDC – 616.34-002 
159.9.072 
 
 Sanda Pletikosić Tončić, University of Rijeka, Faculty of Humanities and Social Sciences, 
Department of Psychology, Sveučilišna avenija 4, 51000 Rijeka, Croatia. E-mail: 
spletikosic@ffri.hr 
This study was funded in part by the Ministry of Science, Education, and Sport, Republic 
of  Croatia (Grant Number 009-0092660-2655) and the University of Rijeka (Grant 
Number 13.04.1.3.1). 
91 
 
 
 
Brain-Gut Miscommunication: Biopsychosocial Predictors  
of Quality of Life in Irritable Bowel Syndrome 
 
Sanda Pletikosić Tončić and Mladenka Tkalčić 
University of Rijeka, Faculty of Humanities and Social Sciences,  
Department of Psychology, Croatia 
 
Goran Hauser 
University of Rijeka, Division of Gastroenterology, Department of Internal Medicine, 
Clinical Hospital Centre Rijeka, Medical Faculty Rijeka,  
Faculty of Health Studies Rijeka, Croatia 
 
 
Abstract 
 
Irritable bowel syndrome (IBS) is a complex disorder that results from interactions of numerous 
factors. The biopsychosocial model describes a number of predisposing, precipitating, and 
perpetuating factors, which contribute to the onset and maintenance of symptoms and consequently 
to quality of life (QoL) impairment. The aim of this study was to examine the impact of several 
psychological and biological factors on the physical and mental components of QoL in IBS patients. 
A total of 46 IBS patients completed a set of questionnaires (Big Five Inventory, State-Trait Anxiety 
Inventory, Beck Depression Inventory-II, Medical Outcome Study Short-Form 36) and kept a diary 
of their mood, daily stress, and symptoms over a period of two weeks. Patients' heart rate variability, 
serum cortisol, and fecal calprotectin levels were also measured. The results of regression analyses 
showed that depression (β = -.30) and negative mood (β = -.28) predicted physical QoL, while 
depression (β = -.45) and positive mood (β = .33) significantly predicted mental QoL. The model, 
which included calprotectin, cortisol, anxiety, depression, and positive and negative mood, 
explained a total of 47% of variance of physical and 57% of variance of mental QoL. Our results 
confirm the role of negative affect in IBS QoL impairment. They also indicate that biological factors 
seem important for physical QoL in IBS patients. The role of positive mood as a protective factor 
for mental QoL might be significant for psychological interventions with IBS patients. 
Keywords: Biopsychosocial model, Irritable bowel syndrome, quality of life, depression, 
positive and negative mood 
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Introduction 
 
When Engel (Engel, 1977) proposed the biopsychosocial (BPS) model of health 
and disease, the door for understanding functional disorders opened. Accordingly, 
this model provides the conceptual basis for defining, understanding, and treating 
functional gastrointestinal (GI) disorders (Drossman, 1998; Drossman, Camilleri, 
Mayer, & Whitehead, 2002; Drossman & Hasler, 2016; Surdea-Blaga, Baban, 
Nedelcu, & Dumitrascu, 2016). It is now clear that irritable bowel syndrome (IBS), 
one of the most common functional GI disorders, results from complex bi-directional 
interactions of biological, psychological, and social factors (Muscatello, Bruno, 
Scimeca, Pandolfo, & Zoccali, 2014; van der Veek, Dusseldorp, van Rood, & 
Masclee, 2010; van Tilburg, Palsson, & Whitehead, 2013). Models that integrate 
those factors are necessary to explain the heterogeneity and complexity related to this 
condition (Spence & Moss-Morris, 2007). IBS is a global disorder whose symptoms 
are often accompanied by psychological dysfunction such as anxiety and depression, 
and by a significant impairment of health-related quality of life (Enck et al., 2016; 
Ford et al., 2014; Lackner et al., 2007; Mykletun et al., 2010; Quigley, 2006; Sibelli 
et al., 2016; Sood, Gracie, Law, & Ford, 2015; Tang, Lin, & Zhang, 2013). Even 
though a respectable amount of research on IBS exists, it is still a poorly understood 
disorder, leaving an urgent need for understanding its pathophysiology and finding 
effective treatment.  
According to the BPS model (Drossman et al., 2002; Van Oudenhove et al., 
2016), the integrated effects of altered physiology and the person's psychosocial 
status will determine the illness experience and the clinical outcome. More 
specifically, the model postulates that biological and psychosocial predisposing 
factors-such as genetics, trauma, parental illness behavior, and personality traits (e.g., 
neuroticism), among others-increase a person's susceptibility to developing IBS. 
Furthermore, precipitating and perpetuating factors (e.g., gut infection, stressful life 
events, social support, and affective status) contribute to the onset and the 
maintenance of symptoms over time (Deary, Chalder, & Sharpe, 2007; Hauser, 
Pletikosic, & Tkalcic, 2014; Hubbard et al., 2015).  
The bi-directional communication system between the brain and the gut with its 
microbiota and immune system, known as the brain-gut axis, serves as the 
neurophysiological mechanism that explains the link between psychological, 
biological and social aspects of IBS (Enck et al., 2016; Jones, Dilley, Drossman, & 
Crowell, 2006; Katsanos, Giannopoulos, & Tsivgoulis, 2012; Van Oudenhove et al., 
2016). According to this conceptualization, IBS symptoms are clinical 
manifestations of "miscommunication" between the gut and the affective-cognitive 
and emotional motor systems of the brain (Fichna & Storr, 2012; Lackner et al., 
2010; Van Oudenhove et al., 2016). 
Psychological distress is an important risk factor for the development and 
maintenance of IBS symptoms (recurrent abdominal pain or discomfort associated 
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with altered defecation), but it can also occur because of disease burden (Van 
Oudenhove et al., 2016). This means that abdominal symptoms can influence anxiety 
and depression and vice versa; psychosocial factors can influence physiological 
factors, such as motor function or stress reactivity of the gut (Fond et al., 2014). 
Epidemiological studies show that anxiety and depression are more common in IBS 
patients compared with controls (Myers & Greenwood-Van Meerveld, 2009; Sibelli 
et al., 2016; Zijdenbos, de Wit, van der Heijden, Rubin, & Quartero, 2009). In a 
recent systematic review, Sibelli (Sibelli et al., 2016) showed that the risk for 
developing IBS at follow-up was double for persons with higher anxiety and 
depression at baseline, compared to those with lower levels. Similarly, neuroticism, 
somatization, and stress (chronic and acute) have all been linked to the onset and 
course of IBS (Sasaki, 2003; Spence & Moss-Morris, 2007). Research shows that 
IBS patients have higher levels of neuroticism as a personality trait than healthy 
persons (Farnam, Somi, Sarami, & Farhang, 2008; Tkalcic, Hauser, & Stimac, 2010) 
and neuroticism has often been linked to higher pain reports in IBS patients (Tanum 
& Malt, 2000). Findings on the role of other personality traits (e.g., extraversion, 
conscientiousness) have been inconsistent. IBS patients report more frequent 
stressors and more extensive effects of stressful events on everyday life than controls 
(Myers & Greenwood-Van Meerveld, 2009). Research also shows that daily levels 
of stress and daily mood have significant effects on both symptom severity and 
quality of life (Blanchard et al., 2008; Pletikosic & Tkalcic, 2016).  
Psychological processes can influence various aspects of GI function through 
efferent brain-gut pathways  ̶  the autonomic nervous system and the hypothalamo-
pituitary-adrenal hormonal system (Van Oudenhove et al., 2016). For instance, 
negative affect plays a key role in the dysregulation of the brain-gut axis, contributing 
to most pathophysiological and symptomatic correlates of IBS (Mayer, 2000; 
Muscatello et al., 2014). Mayer (Mayer, 2000) emphasized that stress-induced 
alterations in autonomic regulation, both sympathetic and parasympathetic, have an 
important role in the modulation of secretion, motility, inflammation, and sensory 
response of the gut. Some of these peripheral alterations can influence brain structure 
and function, setting up circular regulatory loops between the gut and the brain (Enck 
et al., 2016). 
Autonomic dysfunction has been associated with IBS such that persistent 
alterations of autonomic responsiveness play a role in altered bowel habits and 
alterations in gastric emptying, as well as in altered visceral perception (Katsanos et 
al., 2012; Mayer, 2000). Most studies that tried to characterize autonomic 
dysfunction in patients with IBS by means of heart rate variability (HRV), a non-
invasive measure of autonomic function, reported no difference in HRV when the 
IBS population was compared to healthy controls. However, when comparing 
subgroups of IBS patients according to their predominant bowel symptoms, the 
severity of the clinical course, the presence of depressive symptoms, or a history of 
abuse, results revealed changes in autonomic functioning (Mazurak, Seredyuk, 
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Sauer, Teufel, & Enck, 2012). Similarly, the results of a meta-analysis (Liu, Wang, 
Yan, & Chen, 2013) reported that impaired parasympathetic functioning and 
abnormal sympathovagal balance may be involved in the pathogenesis of IBS, with 
more obvious vagal dysfunction found in IBS patients with predominant 
constipation. Several studies have reported a relationship between anxiety and 
depression with altered ANS function in IBS (Jones et al., 2006; Punyabati, Deepak, 
Sharma, & Dwivedi, 2000). For example, Punyabati et al. (2000) showed that 
parasympathetic reactivity was significantly increased in IBS patients compared to 
controls and their anxiety score was significantly higher. Based on the results of a 
meta-analysis, Tak et al. (2009) concluded that available evidence is not adequate to 
firmly reject or accept the role of autonomic dysfunction in IBS due to heterogeneous 
and inconsistent results.  
In addition to autonomic dysfunction, the HPA axis activated by stressors plays 
an important role in functional visceral syndromes characterized by chronic 
discomfort and pain (Chang et al., 2009; Mayer, 2000). Correlations among daily 
stress, anxiety, depression, and GI symptoms indicate that HPA axis dysregulation 
may be an important component of IBS symptomatology (Myers & Greenwood-Van 
Meerveld, 2009). Increased expression and release of CRF in IBS patients are 
consistent with the reported evidence for increased sympathetic responses (Mayer, 
2000). In their well-designed experimental study, Kennedy et al. (Kennedy, Cryan, 
Quigley, Dinan, & Clarke, 2014) used the Trier Social Stress Test - a standardized 
laboratory-based psychosocial stress task - and found that, following acute 
psychosocial stress, patients with IBS exhibit a more sustained HPA axis response 
(total salivary cortisol output) when compared to healthy controls, with an increase 
in self-reported GI symptomatology. It seems that for IBS and depressive patients, 
HPA-axis dysregulation is an important etiological factor (Karling, Wikgren, 
Adolfsson, & Norrback, 2016), but inconsistency related to the existence of hypo or 
hypercortisolism in both conditions is still present.  
It is possible that psychosocial factors modulate the immune response of the gut 
to infectious agents which can cause low level inflammation in the bowel (Fichna & 
Storr, 2012). Due to this hypothesis, there is a growing interest to identify and 
validate biological markers that help in diagnosing functional GI disorders, such as 
IBS (Mujagic et al., 2016). One of those markers which proved to be significantly 
altered in IBS patients compared to individuals in the healthy control group is fecal 
calprotectin, pointing to a low-grade pro-inflammatory state in an IBS patient 
subgroup (Mujagic et al., 2016; Pletikosic, Plavsic, Hauser, & Tkalcic, 2015). 
Furthermore, our preliminary results (Pletikosic et al., 2015) indicate that fecal 
calprotectin levels significantly correlate with the physical component of health-
related quality of life (HRQoL). 
It is doubtless and clear that, regardless of still unsatisfactory and insufficient 
understanding of IBS pathophysiology, this GI disorder considerably reduces the 
patients' quality of life (Enck et al., 2016; Kennedy et al., 2014; Muscatello et al., 
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2014; Van Oudenhove et al., 2016). HRQoL is an important outcome measure in 
IBS, and it is related to both the physical and the psychological aspects of symptom 
severity. Numerous studies show that IBS patients experience a significant 
impairment in HRQoL compared to patients with other chronic disorders, as well as 
compared to healthy persons (Frank et al., 2002; Gralnek, Hays, Kilbourne, Naliboff, 
& Mayer, 2000; Lackner et al., 2007; Spiegel et al., 2004; ten Berg, Goettsch, van 
den Boom, Smout, & Herings, 2006). A variety of factors may contribute to patients' 
HRQoL (Wong & Drossman, 2010). For example, Palsson et al. (Palsson, Jones, 
Turner, Drossman, & Whitehead, 2002) found that the severity and the frequency of 
symptoms affect HRQoL in IBS, that the presence of multiple non-GI physical 
symptoms is associated with worse HRQoL, and that depression worsens HRQoL in 
IBS, even when controlling for the severity of symptoms.  
It seems that the search for factors involved in HRQoL impairment in IBS is 
still ongoing, with important parts of this complex puzzle missing. Therefore, the 
main goal of this study was to examine the impact of various - psychological 
(personality traits and affect, daily mood, stress intensity, perceived symptom 
severity) and biological (calprotectin, cortisol, and HRV) components of the BPS 
model on the physical and mental components of general HRQoL in IBS patients. 
More specifically, the goal was to determine the specific contribution of biological 
and psychological factors to quality of life impairment in IBS patients. 
 
 
Materials and Methods 
 
The study was approved by the Ethics Committee of the Clinical Hospital 
Centre in Rijeka and all participants signed an informed consent form. All procedures 
were in accordance with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards. 
 
Participants 
 
The sample consisted of 46 IBS patients (34 female, 12 male) recruited at the 
Gastroenterology Department of the Clinical Hospital Centre in Rijeka, Croatia. 
Patients were diagnosed based on Rome III criteria. The participants' age ranged 
from 18 to 69 years (M = 44.42, SD = 13.90); most were married or living with a 
partner (65.2%), employed (58.7%), and had a high school education (69.6%). Illness 
duration ranged from 1 to 51 years, with a duration of 1 year in 22.7% of participants, 
a duration of 2-4 years in 28.3% of participants, 5-10 years in 26% of participants, 
and over 10 years in 19.8% of participants. 
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Measures 
Psychosocial Measures 
 
The Big Five Inventory (BFI) (John & Srivastava, 1999; Kardum, Gračanin, & 
Hudek-Knežević, 2006) was used to measure five personality factors: neuroticism, 
extraversion, conscientiousness, agreeableness, and openness. BFI consists of 44 
items in the form of short phrases based on adjectives typical of the five personality 
traits. Participants respond on a five-point scale indicating their degree of agreement 
with each item (1 - completely disagree, 5 - completely agree). Previous studies on 
Croatian samples have replicated the original questionnaire structure, with Cronbach 
alphas ranging from .72 to .82 (Kardum et al., 2006).  
The State-Trait Anxiety Inventory (STAI-T) (Spielberger, 2000) measures the 
dispositional tendency towards anxiety (trait anxiety), and it consists of 20 items. 
Participants respond on a four-point scale, assessing how often they feel a certain 
way in general. A higher score indicates a higher proneness to anxiety. This 
questionnaire has high reliability (α = .91) (Spielberger, 2000).  
The Beck Depression Inventory-II (BDI-II) (Beck, Steer, & Brown, 2011) 
measures the severity of psychological symptoms of depression using 21 items. 
Answers are given on a scale from zero to three, assessing the frequency and the 
intensity of the listed symptoms. Reported reliability coefficients are quite high 
(Cronbach α = .90 for student samples, and .93 for clinical samples) (Beck et al., 
2011). 
The Medical Outcome Study Short-Form 36 (SF-36) (Tkalčić, Hauser, Štimac, 
& Pokrajac-Bulian, 2007; Ware & Sherbourne, 1992) measures both physical and 
mental health-related QoL. Specifically, it includes four domains of physical health 
(physical functioning, role limitation [physical], bodily pain, and general health) and 
four domains of mental health (role limitation [emotional], vitality, mental health, 
and social functioning). It is possible to obtain eight final scores (one for each 
domain) and two final summary scores—the physical component summary, which 
has 21 items, and the mental component summary, which has 14 items. Participants 
respond to different questions either with yes-no answers, on a 3-point scale (how 
limited do they feel by their health; 1 - limited a lot, 3 - not limited at all), on a 5-
point scale (indicating the degree to which items hold true for them; 1 - completely 
true, 5 - completely false), or on a 6-point scale (indicating the amount of time spent 
feeling a certain way; 1- all of the time, 6 - none of the time). Participant responses 
are transformed and summed to provide scores between 0 and 100 with higher scores 
reflecting better health-related QoL (Ware & Sherbourne, 1992). 
Several scales were used in the longitudinal part of the study and were 
completed either three times a day, in the morning, afternoon, and evening (daily 
mood and symptom severity) or once daily (daily stressful events) for two weeks. 
For all of these measures, 42 (or 14) measurement time points were obtained, but in 
the following analyses, the mean score of each measure was used for each participant. 
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Daily mood was measured using an abbreviated version of the Mood Scale 
(Kardum & Bezinović, 1992). The scale measures seven first order factors and two 
higher order factors: positive mood (PM; consisting of joy, activation, and 
acceptance) and negative mood (NM; consisting of sadness, anger, rejection, and 
fear). The abbreviated version used in this study has 15 items, with two items per 
each lower order factor (except for joy, which has three items) that had the highest 
factor loadings in previous research (Tončić, 2009). The distribution of NM values 
proved to be positively skewed (skeweness = 1.02; kurtosis = 0.45) and was recoded 
as an ordinal variable with three levels, each level containing a third of the sample. 
Patients' symptom severity was measured via the IBS Symptom Severity Scale, 
which was constructed based on the Gastrointestinal Symptom Diary (Blanchard, 
2001). It contains eight symptoms (constipation, diarrhea, abdominal pain, 
abdominal tenderness, bloating, nausea, flatulence, belching), and the participants 
must rate the severity of each symptom on a scale from zero (absent) to four 
(debilitating).  
Patients' daily stressful events were measured using the Daily Stressful Events 
Scale, which was constructed based on the stressful events classification from the 
manual for coding interviews of the Daily Inventory of Stressful Events (DISE) 
(Almeida, 1998). Patients marked whether they experienced any of the seven types 
of stressful events (related to e.g., health, finances, family relationships), how many 
such events they experienced per type, and for each type they marked how stressful 
it was from one (slightly stressful) to four (very, intensely stressful).  
Descriptive data for BFI, STAI-T, BDI-II, SF-36, symptom severity and stress 
intensity are shown in Table 1. 
 
Table 1  
 
Descriptive Data for the Scales Used in the Study 
 
Scale M SD 
Obtained 
range 
Cronbach 
alpha 
Neuroticism 24.61 4.94 16 - 35 .73 
Extraversion 27.67 5.91 12 - 39 .82 
Openness 36.30 6.09 26 - 49 .78 
Conscientiousness 34.33 5.94 21 - 43 .85 
Agreeableness 34.50 5.67 22 - 44 .81 
Anxiety 34.72 11.21 14 - 59 .89 
Depression 8.39 6.51   0 - 24 .82 
SF-36 physical component 75.90 13.81 41.43 - 97.86 .82 
SF-36 mental component 67.20 18.02 32.14 - 95.36 .88 
Positive mood 2.37 0.49 1.19 - 3.27 / 
Negative mood 0.54 0.42      0 - 1.70 / 
Symptom severity 1.52 0.29 1.04 - 2.10 / 
Stress intensity 0.89 0.64      0 - 2.74 / 
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Biological Measures 
 
Several indirect biological measures were used: serum cortisol, fecal 
calprotectin, and heart rate variability.  
To record a marker of HPA activity, serum cortisol levels were obtained from 
one blood sample, collected during the morning hours. Electrochemiluminescent-
immunological method (ECLIA) was used, with possible cortisol values ranging 
from 0.5 to 1750 nmol/L. Reference values for healthy persons range from 171 to 
536 nmol/L in the morning and from 64 to 327 nmol/L in the afternoon (Elecsys 
Cortisol Assay).  
As an indirect measure of gut inflammation, fecal calprotectin levels were 
obtained from one stool sample. An immunoenzyme assay was used to determine 
the quantitative levels of calprotectin (Quantum Blue Calprotectin), with possible 
values ranging from 30 to 300 μg/g. Research shows that a cut-off value of 50 μg/g 
has high sensitivity (above 95%), and a somewhat lower specificity (74%), which 
indicates that calprotectin levels under 50 μg/g should be considered normal (Waugh 
et al., 2013). The distribution of calprotectin values was positively skewed 
(skeweness = 4.97; kurtosis = 28.02) and was transformed into an ordinal variable, 
with values of less than 30 μg/g (which the test could not detect) treated as zero 
calprotectin, values between 30 and 50 μg/g treated as low calprotectin, and values 
above 50 μg/g as medium to high calprotectin.  
As a marker of autonomic function, heart rate variability (HRV) was measured. 
In order to monitor heart rate, we used Polar RS 800 devices, which consist of a chest 
strap with a transmitter and electrodes and a wrist watch with a receiver and data 
storage. The patients recorded their heart rates for 15 minutes, three times a day 
(morning, afternoon, and evening), for two weeks. The final five minutes of each 
measurement time point were extracted. A power spectral analysis was performed 
using a fast Fourier transform with HRV Analysis Software (Niskanen, Tarvainen, 
Ranta-Aho, & Karjalainen, 2004) in order to calculate power spectral density, or high 
frequency (HF) and low frequency (LF) HRV measured in absolute power values 
(ms2). Sympathovagal balance (LF/HF HRV) was calculated by dividing LF HRV 
by HF HRV. 
Table 2 shows average values and obtained ranges for cortisol, calprotectin and 
HRV measures. 
 
Table 2 
Descriptive Data for Cortisol, Calprotectin, and Heart Rate Variability (HRV) 
Measures: Low Frequency HRV, High Frequency HRV and Low : High HRV Ratio 
Measure M SD Obtained range 
Cortisol 367.08 148.94 102.90 -   830.90 
Calprotectin 47.95 43.50 30.00 -   300.00 
LF HRV 379.69 398.53 5.24 - 1649.42 
HF HRV 228.12 289.74 1.54 - 1484.07 
LF/HF HRV 3.31 2.63 0.76 -     13.30 
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Procedure 
 
Data was collected from January 2012 to October 2013. Participants were 
recruited at the Clinical Hospital Centre in Rijeka, Croatia. They participated in the 
study in small groups (two to seven people). For each group of participants, the study 
had three parts (illustrated in Figure 1). In the first part, the participants completed a 
set of questionnaires (general information, BFI and STAI-T). Each participant 
individually carried out the second part over the course of two weeks. They 
completed the Mood Scale, the IBS Symptom Severity Scale, and measured their 
heart rate for 15 minutes while abstaining from all other activities three times each 
day (within two hours of waking up, between 16:00 and 18:00 in the afternoon, and 
within two hours of going to sleep). During the third daily measurement time point, 
they also completed the Daily Stressful Events Scale. Participants were reminded 
about each measurement time point via mobile phone text message. During those 
two weeks, participants also gave one blood sample (for serum cortisol) and one stool 
sample (for fecal calprotectin). After the two-week period, the participants completed 
a final set of questionnaires (BDI-II, SF-36). 
 
 
Figure 1. Timetable of the study design. The study was comprised of three parts. Part one and 
part three consisted of completing a set of questionnaires and were carried out at the Clinical 
Hospital Centre in Rijeka. The second part lasted 14 days and was carried out at home by 
each participant individually. They were required to complete a diary consisting of several 
scales and to record their heart rate. During those 14 days participants were required to give 
one blood sample and one stool sample for determining their serum cortisol levels and fecal 
calprotectin levels, respectively. 
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Results 
 
To estimate the impact of individual components of the BPS model on QoL in 
IBS patients, we performed two hierarchical regression analyses. Due to the large 
number of predictors (16) and the relatively small number of participants (43 for the 
indirect biological measures, 46 for all other measures) we could not use all predictors 
in the same analyses. We decided to select 2 predictors from each group of predictors, 
resulting in a total of 6 predictors which were used in the hierarchical regression 
analyses. Two predictors with the highest correlations with the outcome variables 
were selected (marked in bold in Table 3). The outcome variables used were the two 
composite scores of the SF-36: the physical and the mental component. Predictors 
were grouped based on their similarity: indirect biological measures (calprotectin, 
cortisol, HRV), traits and affect measured once via questionnaires (BFI, STAI-T, 
BDI-II), and longitudinal data averages calculated from the diary data (mood, 
symptom severity, stress intensity). Since calprotectin and negative mood (NM) 
scores were transformed onto an ordinal scale with three levels, dummy coding was 
used in the analyses: medium and high levels were compared with low levels for both 
calprotectin and NM. Table 3 shows correlation coefficients of all predictors with both 
outcome variables. 
 
Table 3 
Pearson Correlation Coefficients between Quality of Life Composite Scores and Their 
Possible Determinants, Grouped by Type of Measurement 
Predictors 
SF-36 physical 
component 
SF-36 mental 
component 
Biological measures 
High vs. Low Calprotectin -.39* -.28 
Medium vs. Low Calprotectin -.04 .10 
Cortisol .11 -.22 
LF HRV .13 -.01 
HF HRV .12 -.03 
LF/HF HRV .02 .10 
Traits and affect   
Neuroticism -.25 -.25 
Extraversion .41** .32* 
Openness .30* .06 
Conscientiousness .16 .23 
Agreeableness  -.12 .09 
Anxiety -.49** -.38** 
Depression -.51** -.59** 
Longitudinal averages   
Positive mood .25 .44** 
High vs. Low Negative Mood -.50** -.46** 
Medium vs. Low Negative Mood .16 .01 
Stress intensity -.19 -.30* 
Symptom severity -.07 -.06 
*p < .05; **p < .01. 
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The physical component of SF-36 had the highest correlation with calprotectin, 
while the mental component had the highest correlations with calprotectin and 
cortisol. Participants with calprotectin levels above 50 μg/g had significantly lower 
physical and mental QoL than participants with lower levels of calprotectin. In 
addition, higher levels of cortisol were related to lower mental QoL.  
Even though several traits had significant correlations with one or both 
measures of QoL, depression and anxiety showed the highest correlations with both 
outcome variables. Participants with higher depression and higher anxiety scores had 
lower QoL.  
In the final group of predictors - averages of longitudinally collected data - 
positive (PM) and negative mood (NM) had the highest correlations with the 
outcome variables. Participants with the highest average NM had significantly lower 
physical and mental QoL than participants with lower NM averages. In addition, 
participants with higher PM averages had higher mental QoL. 
All of the predictors described above were used in the two hierarchical 
regression analyses. The selected predictors were only mildly intercorrelated 
(Mabsolute r = .28; maximum r = .49). A chronological approach was taken for variable 
entry into the regression model, with biological measures - calprotectin and cortisol 
- entered in the first step, traits and long-term mood - depression and anxiety - 
introduced in the second step, and averages of daily mood - PM and NM - entered in 
the final step of the regression analyses (Tables 4 and 5). 
Due to the small sample size, 95% confidence intervals of each estimated 
parameter were calculated using bootstrapped samples (N of samples = 1000). 
As shown in Tables 4 and 5, the empirically derived confidence intervals closely 
resemble the results of conventional parameter significance testing. 
Table 4 
Results of a Hierarchical Regression Analysis for the Physical Component of Quality of 
Life (With Bootstrap Confidence Intervals) 
 
SF-36 physical 
component 
Predictors Estimate Bootstrap 95% CI β ∆R2 R2 
Step 1    .15* .15* 
Intercept 80.1952 70.0014;    93.4531    
High vs. Medium and 
Low Calprotectin 
-12.7813 -22.6967;    -2.8180 -.40*   
Cortisol -0.0026 -0.0354;     0.0175 -.03   
Step 2    .26** .41** 
Intercept 90.0584 76.0144; 109.5810    
High vs. Medium and 
Low Calprotectin 
-5.7846 -15.9830;     5.1661 -.18   
Cortisol 0.0110 -0.0218;     0.0339 .12   
Anxiety -0.2578 -0.7656;     0.1068 -.20   
Depression -0.9278  -1.5808;    -0.1060 -.42*   
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Table 4 - Continued.     
 
SF-36 physical 
component 
Predictors Estimate Bootstrap 95% CI β ∆R2 R2 
Step 3    .06 .47** 
Intercept 81.4112 56.7886; 105.9956    
High vs. Medium and 
Low Calprotectin 
-4.5189 -16.0583;     8.3143 -.14   
Cortisol 0.0184 -0.0185;     0.0480 .19   
Anxiety -0.1959 -0.6913;     0.1536 -.15   
Depression -0.6668 -1.3837;     0.4054 -.30†   
Positive Mood 1.6751 -6.0991;   10.3227 .06   
High vs. Medium and 
Low Negative Mood 
-8.3491 -20.6410;     3.7270 -.28†   
†p < .10; *p < .05; **p < .01. 
 
Table 5  
Results of a Hierarchical Regression Analysis for the Mental Component of Quality of Life 
(With Bootstrap Confidence Intervals) 
   SF-36 mental component 
Predictors Estimate Bootstrap 95% CI β ∆R2 R2 
Step 1    .19* .19* 
Intercept 88.1287 76.8686; 101.3753    
High vs. Medium and 
Low Calprotectin 
-15.5857 -28.2827;   -3.5064 -.40*   
Cortisol -0.0418 -0.0806;   -0.0123 -.36*   
Step 2    .25** .44** 
Intercept 92.4656 65.9736; 113.8010    
High vs. Medium and 
Low Calprotectin 
-7.5433 -18.2182;     5.0202 -.19   
Cortisol -0.0210 -0.0599;     0.0235 -.18   
Anxiety -0.0650 -0.5661;     0.4929 -.04   
Depression -1.3982 -2.5820;    -0.6121 -.52**   
Step 3    .13* .57** 
Intercept 55.8205 19.7878;   84.9981    
High vs. Medium and 
Low Calprotectin 
-3.8942 -16.4151;     8.5626 -.10   
Cortisol -0.0104 -0.0457;     0.0286 -.09   
Anxiety 0.0445 -0.4433;     0.5742 .03   
Depression -1.2123 -2.3641;    -0.4952 -.45**   
Positive Mood 11.9066 2.6444;   21.3216 .33**   
High vs. Medium and 
Low Negative Mood 
-5.9247 -16.7175;   5.7918 -.16   
*p < .05; **p < .01. 
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Biological measures which were entered in the first step of the regression 
analyses explained a significant proportion of variance of physical and mental QoL 
(15% and 19% respectively). Calprotectin was a significant predictor for both criteria 
and cortisol significantly predicted only the mental QoL. After anxiety and 
depression were added in the second step, the biological measures were no longer 
significant predictors. Anxiety and depression explained an additional 26% and 25% 
of QoL variance. In the third step, PM and NM were added, resulting in a total of 
47% of variance explained for the physical QoL and 57% for the mental QoL. 
Depression and NM were marginally significant (p < .10) predictors of physical QoL, 
while depression and PM were significant predictors of mental QoL. Participants 
with higher depression scores had lower QoL, those with higher PM had higher 
mental QoL, while those with the highest NM had lower physical QoL. 
To test whether biological measures predict QoL beyond psychological 
measures, we performed two additional hierarchical regression analyses, one for each 
QoL measure, and we entered the biological measures in the second step, after 
psychological variables were already included in the model. For physical QoL, 
biological measures explained an additional 6.5% of variance (p = .12; calprotectin 
β = -.14 and cortisol β = .19, both non-significant), but for mental QoL they did not 
improve the model fit significantly (∆R2 = .009). 
 
 
Discussion 
 
The goal of this study was defined by the constant need to understand the 
communication between the brain and the bowel through the relationship between 
biological and psychosocial factors, and building upon the present knowledge 
derived from the BPS model. The BPS model is very broad, which makes it 
impossible to consider all relevant factors simultaneously; however, we decided to 
include several factors from each aspect of the model.  
After analyzing correlations of each aspect of the BPS model with QoL 
separately, the final regression models contained predictors with the highest 
correlations. In the final step of the hierarchical regression, as shown in the full 
model, the individual contribution of biological predictors is not significant. 
However, by reversing the model building strategy, we found that calprotectin and 
cortisol explain an additional 6.5% of the physical component of QoL (although p = 
.12). Even though all participants had clinically insignificant levels of calprotectin, it 
seems that levels above 50μg/g can differentiate IBS patients with QoL impairment. 
Although there are no previous studies linking calprotectin levels to QoL impairment 
in IBS patients, there are studies showing calprotectin's relation to endoscopic 
disease activity in IBD patients, with an accuracy of 89% in discriminating between 
different severities of disease activity (Schoepfer et al., 2009). In addition, it seems 
that IBD patients in remission, who have IBS-like symptoms, also have higher 
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calprotectin levels than IBD patients in remission without IBS-like symptoms 
(Keohane et al., 2010). This relationship might reflect a link between IBS-like 
symptoms and microscopic inflammation in the absence of structural disease in IBD 
patients (Long & Drossman, 2010). Similarly, the presence of calprotectin in IBS 
patients with impaired QoL could suggest that a low-grade inflammation is a relevant 
component of IBS, at least in a subset of patients. It is important to note that there 
have been many studies reporting alterations in inflammatory and immune 
parameters in IBS patients, such as leukocytes, mast cells, and immunoglobulins 
(Elsenbruch, 2011; Ortiz-Lucas, Saz-Peiro, & Sebastian-Domingo, 2010), which 
could be indicative of low-grade inflammation. The obtained serum cortisol levels 
were also mainly within the reference range; however, in this sample, patients with 
higher levels reported better physical quality of life. This is in line with the findings 
suggesting a relationship between functional pain symptoms and decreased cortisol 
levels, and depressed mood and elevated cortisol levels (Ehlert, Gaab, & Heinrichs, 
2001; Ehlert, Nater, & Bohmelt, 2005; Karling et al., 2016). If hypocortisolism is 
indeed related to reports of severe pain and physical symptoms in IBS patients, then 
we would expect patients with higher cortisol levels to have a better physical quality 
of life, which is what the results show. On the other hand, if higher cortisol levels are 
related to depressed mood, we would expect a correlation between cortisol and 
depression, which was not significant (r = .22); however, cortisol had a marginally 
significant correlation with negative mood (r = .29; p = .058).  
For mental QoL however, even though calprotectin and cortisol were significant 
predictors of mental QoL when entered as the only predictors, we found that they do 
not add to the explanation of mental QoL when they are entered after psychological 
measures. These findings could indicate the involvement of the HPA axis 
dysregulation in QoL impairment of IBS patients, at least in the case of physical QoL. 
In our data, HRV measures had no significant correlations with QoL measures. Some 
previous studies on HRV in IBS have reported increased sympathetic and decreased 
parasympathetic activity in patients regardless of their subtype (Pellissier, Dantzer, 
Canini, Mathieu, & Bonaz, 2010), while others reported this pattern in patients with 
predominating constipation (Mazur et al., 2007), and some observed it only in female 
patients with severe symptoms (Cain, Jarrett, Burr, Hertig, & Heitkemper, 2007). 
Since there are no findings linking HRV to QoL in IBS, it is possible no such 
connection exists, that it might be mediated by symptom severity, or that it is only 
observable when using postprandial HRV data. We need to point out that biological 
measures and self-report data are qualitatively different, which inevitably results in 
lower correlation coefficients compared to those found among self-report measures. 
The results of this study show that depression significantly contributes to both 
physical and mental QoL in IBS patients. Many studies have shown a link between 
depression and IBS, whether as higher depression levels found in IBS patients 
compared to healthy persons (Fond et al., 2014; Ladep, Obindo, Audu, Okeke, & 
Malu, 2006), a high comorbidity of IBS and depression (Cho et al., 2011; Lee et al., 
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2017), or as the predictive value of depression for developing IBS (Nicholl et al., 
2008). Higher depression levels have been associated with higher symptom severity 
scores (Cho et al., 2011; Pletikosic & Tkalcic, 2016), as well as quality of life 
impairment in IBS patients (Cho et al., 2011; Creed et al., 2001; Tkalcic et al., 2010). 
Although it is not completely clear what the mechanism of this association is, the 
most plausible one is a circular relationship, possibly including several other 
psychological states. Patients suffering from chronic conditions, whose QoL is 
impaired, tend to have higher depression scores, however the opposite is also true—
depressed mood can lead to higher disability and lower QoL. It is possible that this 
relationship is mediated by stressful events, the onset of depression being usually 
preceded by stressful life events (Mazure, 1998), and depressed persons being prone 
to interpreting events as negative (Beck et al., 2011), making the relationship a closed 
circle (Hammen, 2005). It is necessary to mention a possible methodological issue 
regarding the high correlations (and beta coefficients) between depression and QoL. 
Since both measures were completed at the same time, the fact that they are both self-
report measures could have artificially inflated the magnitude of their relationship. 
The only personality trait entered in the regression analysis was anxiety, showing the 
highest correlations with both QoL measures. Entered in the second step of the 
regression analysis, anxiety and depression explained 26% and 25% of the physical 
and mental QoL variance, however trait anxiety was not a significant predictor of 
neither physical nor mental QoL. Research consistently shows that IBS patients have 
higher anxiety levels than healthy controls (Fond et al., 2014). Higher trait anxiety 
and anxiety related states, such as visceral anxiety are associated with reduced QoL 
in iBS patients (Jerndal et al., 2010; Labus et al., 2004; Muscatello, Bruno, Mento, 
Pandolfo, & Zoccali, 2016). Patients prone to worry, ruminative thoughts and 
catastrophizing, who tend to focus on their symptoms in a very anxious manner - 
worrying about their significance and anticipating their exacerbation, also tend to 
report QoL impairment. Thus, anxiety related states are often considered to be among 
the key components of symptom perpetuation in IBS patients (Hauser et al., 2014). 
The results of this study however, seem to indicate that depressed or negative mood 
is more detrimental to QoL than trait anxiety, but this cannot be generalized to the 
role of state anxiety. As Table 3 shows, other personality traits, namely extraversion 
and marginally neuroticism, correlated with mental and physical QoL. Even though 
they were not included in the regression analyses, we consider them relevant for the 
BPS model of IBS. However, compared to anxiety and depression, broad personality 
dimensions seem to have weaker relationships with IBS outcome variables. One 
possible explanation is that anxiety and depression are more proximally related to 
QoL especially in relation to content, but in the case of depression also in relation to 
time of measurement (Figure 1), as explained previously. 
The two final predictors - negative and positive mood - were, unlike depression, 
measured daily and analyzed as two-week averages. This type of measurement 
provides a more stable and realistic representation of the patients' moods. For the 
physical component of QoL, the finding on the involvement of negative mood in 
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QoL impairment is in line with previous studies (Lee et al., 2008; Muscatello et al., 
2014, 2016; Pellissier et al., 2010; Rey, Garcia-Alonso, Moreno-Ortega, Alvarez-
Sanchez, & Diaz-Rubio, 2008; Spiegel et al., 2004) which reported a significant 
impact of psychological distress (anxiety, depression, negative mood, somatization, 
stress) on QoL, as well as on symptom severity. The resulting consensus on the 
importance of psychological distress has shaped the vast majority of psychological 
interventions, most of which predominantly focus on QoL improvement and 
symptom alleviation through the reduction of psychological distress (Surdea-Blaga 
et al., 2016). Because of this, the most interesting finding of this study is the 
significance of positive mood for predicting mental QoL. Patients who reported 
higher positive mood throughout the two-week period, later showed higher mental 
QoL. Positive mood is related to different positive states such as interest, enthusiasm, 
happiness, motivation, mental alertness, etc., and is generally associated with 
improved physical and mental health (Muscatello et al., 2016). There are indications 
that for long-term illnesses, for which different behavioral factors seem to be 
significant, eliciting positive mood has beneficial effects on symptom improvement 
(Pressman & Cohen, 2005). Based on our results, it seems that psychological 
interventions for IBS should also focus on the patients' positive mood. This could 
help patients redirect their attention from symptoms and negative aspects of their 
disorder to more rewarding stimuli in their environment. The two remaining 
measures obtained from diary data - symptom severity and stress intensity - did not 
have significant correlations with either QoL measure. Although some previous 
studies have reported significant relationships between QoL and pain severity (Lee 
et al., 2008; Rey et al., 2008), there are other findings suggesting that QoL 
impairment in IBS patients is more affected by psychological states than the severity 
of symptoms (Michalsen, Vandvik, & Farup, 2015). Finally, even though self-
reported stress intensity has previously been linked to symptom exacerbation 
(Blanchard et al., 2008), our results indicate that it might not be as relevant to QoL, 
as its resulting psychological states, depression and negative mood, seem to be.  
The described results should be cautiously interpreted, due to several limitations 
of the study. First of all, the small sample size did not permit including all the relevant 
factors in the tested models, but rather forced us to limit the number of factors per 
group of predictors (indirect biological measures, traits and affect, longitudinal 
averages from the diary data). Although this approach seems rather arbitrary, it was 
a trade-off which allowed us to include the most relevant predictors from all predictor 
groups. However, such a small sample size limits the generalizability of the obtained 
results, especially when taking into account the heterogeneous nature of IBS. 
In conclusion, this study found indications of a possible role of low-grade 
inflammation and HPA axis dysregulation in physical QoL impairment in IBS 
patients. We also found support for a significant role of depression and mood in both 
physical and mental QoL of IBS patients. Depressed and negative mood have 
previously been linked to low-grade inflammation and immune activity in IBS 
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(Muscatello et al., 2016) and are most probably related through the so-called sickness 
behavior, an effect of proinflammatory cytokines which results in behavior changes 
directed towards conserving resources and minimizing threat exposure. For IBS 
patients, such a depressed state might be a chronic one, reflecting a set of 
psychological traits characterized by negative mood and susceptibility to stress; 
however, in patients with severe QoL impairment, it might have an inflammatory 
component as well, accompanied by a dysregulated stress response. Since low 
cortisol levels are related to both an increased risk of inflammation as well as an 
increased chance for developing depressed mood (Karling et al., 2016), it is not 
surprising to find these in IBS patients with severe QoL impairment. The most 
practically relevant finding of this study is the role of positive mood as a protective 
factor for emotional and social aspects of QoL, highlighting the need for shifting 
therapeutic focus from psychological distress to those activities that elicit positive 
affective states.  
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Obstáculos en la comunicación entre el cerebro y el intestino: 
Predictores biopsicosociales de la calidad de vida en el  
síndrome del intestino irritable 
 
Resumen 
 
El síndrome del intestino irritable (SII) es un trastorno complejo, resultado de la interacción de 
numerosos factores. El modelo biopsicosocial describe algunos factores de predisposición, 
precipitación y perpetuación que contribuyen a la apariencia y mantenimiento de síntomas, y por 
consiguiente, al deterioro de la calidad de vida. El objetivo de este trabajo fue examinar el efecto 
que tienen ciertos factores psicológicos y biológicos sobre los componentes de la calidad de vida en 
los pacientes que sufren SII. Un total de 46 pacientes con SII completaron un conjunto de 
cuestionarios (Inventario de Los Cinco Grandes, Inventario de Ansiedad Estado-Rasgo, Inventario 
de Depresión de Beck II, Cuestionario de Salud SF-36) y durante dos semanas escribían un diario 
sobre su estado de ánimo, estrés diario y síntomas. Además, se midió su variabilidad del ritmo 
cardíaco, cortisol sérico y niveles de calprotectina fecal. Los resultados del análisis regresiva 
mostraron que la depresión (β = -.30) y mal humor (β = -.28) predijeron calidad de vida física, 
mientras que la depresión (β = -.45) y buen humor (β = -.33) predijeron significativamente calidad 
de vida mental. El modelo, que incluyó calprotectina, cortisol, ansiedad, depresión y buen y mal 
humor, explicó el 47% de la varianza de la calidad de vida física y el 57% de la calidad de vida 
mental. Nuestros resultados confirmaron el papel del afecto negativo en el deterioro de la calidad de 
vida en el SII. También indicaron que los factores biológicos parecen importantes para la calidad de 
vida física en los pacientes con SII. El papel del buen humor como un factor protector para la calidad 
de vida mental podría ser significativo para las intervenciones psicológicas en los pacientes con SII. 
 
Palabras clave: modelo biopsicosocial, síndrome del intestino irritable, calidad de vida, 
depresión, buen y mal humor 
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